Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

57.1%

-29.4% vs industry average

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

125%

5 of 4 completed trials have results

Key Signals

3 recruiting5 with results

Enrollment Performance

Analytics

Phase 2

5(50.0%)

Phase 1

3(30.0%)

Phase 3

2(20.0%)

10Total

Phase 2(5)

Phase 1(3)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT03093402Phase 2Completed

JBT-101 in Systemic Lupus Erythematosus (SLE)

Role: collaborator

NCT07310901Phase 1Recruiting

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity

Role: lead

NCT06265727Phase 1Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Role: lead

NCT06603844Phase 1Recruiting

First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.

Role: lead

NCT02466243Phase 2Terminated

Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis

Role: lead

NCT03451045Phase 2Completed

Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Role: lead

NCT03813160Phase 3Completed

Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis

Role: lead

NCT02465437Phase 2Terminated

Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis

Role: lead

NCT03398837Phase 3Terminated

Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis

Role: lead

NCT02465450Phase 2Completed

Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic Fibrosis

Role: lead

All 10 trials loaded